1. Le Loarer F, Watson S, Pierron G, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet 2015; 47: 1200-1205.
2.
Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol 2022; 17: 362-387.
3.
Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Boland JM. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Mod Pathol 2017; 30: 1422-1432.
4.
Perret R, Chalabreysse L, Watson S, et al. SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses. Am J Surg Pathol 2019; 43: 455-465.
5.
Gantzer J, Davidson G, Vokshi B, et al. Immune-desert tumor microenvironment in thoracic SMARCA4-deficient undifferentiated tumors with limited efficacy of immune checkpoint inhibitors. Oncologist 2022; 27: 501-511.
6.
Mundada M, Abdul Mannan K, Vasu D, et al. Under the microscope: a case report of thoracic SMARCA4-deficient undifferentiated tumor with review of the literature. Turk J Pathol 2024; 40: 128-133.
7.
Roden A. Thoracic SMARCA4- deficient undifferentiated tumor-a case of an aggressive neoplasm-case report. Mediastinum 2021; 5: 39-44.
8.
Zhou P, Fu Y, Tang Y, et al. Thoracic SMARCA4-deficient undifferentiated tumor: a clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy. Lung Cancer 2024; 189: 107471.
9.
Crombé A, Alberti N, Villard N, et al. Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients. Eur Radiol 2019; 29: 4730-4741.
10.
Takada K, Sugita S, Murase K, et al. Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: a case report. Thorac Cancer 2019; 10: 2312-2315.
11.
Kawachi H, Kunimasa K, Kukita Y, et al. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. Immunotherapy 2021; 13: 799-806.
12.
Iijima Y, Sakakibara R, Ishizuka M, et al. Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report. Immunotherapy 2020; 12: 563-569.
13.
Nambirajan A, Dutta R, Malik PS, Bubendorf L, Jain D. Cytology of SMARCA4-deficient thoracic neoplasms: comparative analysis of SMARCA4-deficient non-small cell lung carcinomas and SMARCA4-deficient thoracic sarcomas. Acta Cytologica 2020; 65: 67-74.
14.
Rachidi SL, Firmin N, Elfadli M, et al. A Case report of SMARCA4-deficient thoracic sarcoma: a rare and aggressive disease with a grim prognosis. Cureus 2023;15(5): e39571.
15.
Shinno Y, Yoshida A, Masuda K, et al. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient thoracic tumor. Clin Lung Cancer 2022; 23: 386-392.
16.
Stewart BD, Kaye F, Machuca T, et al. SMARCA4-deficient thoracic sarcoma: a case report and review of literature. Int J Surg Pathol 2020; 28: 102-108.
17.
Kunimasa K, Nakamura H, Sakai K, et al. Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events. Lung Cancer 2019; 132: 59-64.
18.
Rekhtman N, Montecalvo J, Chang JC, et al. SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol 2020; 15: 231-247.
19.
Kuwamoto S, Matsushita M, Takeda K, et al. SMARCA4-deficient thoracic sarcoma: report of a case and insights into how to reach the diagnosis using limited samples and resources. Hum Pathol 2017; 70: 92-97.
20.
Yoshida A, Kobayashi E, Kubo T, et al. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol 2017; 30: 797-809.
